Table of Contents
PISCATAWAY, N.Y., – Camber Pharmaceuticals announces the addition of Decitabine for injection.
Decitabine for injection is indicated for treatment of:
- adult patients with myelodysplastic syndromes (MDS)
- de novo and secondary MDS of all French-American British subtypes
- refractory anemia with excess blasts
- chronic myelomonocytic leukemia
Decitabine for injection is available in a 50 mg single-dose vial.
To find out more information on Decitabine for injection, visit: www.camberpharma.com/decitabine
